This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pawlak-Byczkowska, E. J. Articles by Goldenberg, D. M. Search for Related Content PubMed PubMed Citation Articles by Pawlak-Byczkowska, E. J. Articles by Goldenberg, D. M.

Two New Monoclonal Antibodies, EPB-1 and EPB-2, Reactive with Human Lymphoma¹

Immunomedics, Inc. [E. J. P-B., H. J. H.], and the Center for Molecular Medicine and Immunology [A. S. D., D. M. G.], University of Medicine and Dentistry of New Jersey, Newark, New Jersey 07103

Using the Raji cell line as the immunogen source, we established stable murine hybridomas that secrete B-lymphocyte-specific monoclonal antibodies (MAbs). Two clones, designated EPB-1 and EPB-2, were selected for further study. Both EPB-1 and EPB-2 were typed by reaction with subclass-specific rabbit anti-mouse antibodies and were found to be IgG1 and IgG2a, with -light chains, respectively. In radioimmunobinding and flow cytometric assays, EPB-1 and EPB-2 did not react with T-cell lines, nor with normal diploid cells. EPB-2, in contrast to EPB-1, did not react by flow cytometry with normal peripheral or bone marrow leukocytes. In normal lymphoid tissues, both antibodies were positive with germinal center and mantle zone B-lymphocytes. Additionally, EPB-1 also labeled interdigitating histiocytes in the T-cell zones. Both MAbs discriminated very well between lymphoid and nonlymphoid tissues; neither MAb cross-reacted with tested normal and solid tumor tissue specimens, or with cell lines of non-B-cell origin. Immunohistology also revealed that both MAbs stained malignant lymphoma tissue sections and cloned B-cell lymphomas, both in tissue culture and as human xenografts in nude mice. Due to the radiosensitivity of human lymphomas and the relative specificity of these two new MAbs, they appear to be potential radioimmunotherapeutic agents for human lymphoma.

¹ Supported in part by USPHS Grant CA39841 from the NIH.

² To whom requests for reprints should be addressed, at the Center for Molecular Medicine and Immunology, 1 Bruce Street, Newark, NJ 07103.

Received 10/ 6/88. Revised 3/31/89. Accepted 5/15/89.

This article has been cited by other articles:

				Z. Qu, D. M. Goldenberg, T. M. Cardillo, V. Shi, H. J. Hansen, and C.-H. Chang Bispecific anti-CD20/22 antibodies inhibit B-cell lymphoma proliferation by a unique mechanism of action Blood, February 15, 2008; 111(4): 2211 - 2219. [Abstract] [Full Text] [PDF]

				R. Stein, M. J. Mattes, T. M. Cardillo, H. J. Hansen, C.-H. Chang, J. Burton, S. Govindan, and D. M. Goldenberg CD74: A New Candidate Target for the Immunotherapy of B-Cell Neoplasms Clin. Cancer Res., September 15, 2007; 13(18): 5556s - 5563s. [Abstract] [Full Text] [PDF]

				I. Binsky, M. Haran, D. Starlets, Y. Gore, F. Lantner, N. Harpaz, L. Leng, D. M. Goldenberg, L. Shvidel, A. Berrebi, et al. IL-8 secreted in a macrophage migration-inhibitory factor- and CD74-dependent manner regulates B cell chronic lymphocytic leukemia survival PNAS, August 14, 2007; 104(33): 13408 - 13413. [Abstract] [Full Text] [PDF]

				S. J. Strauss, F. Morschhauser, J. Rech, R. Repp, P. Solal-Celigny, P. L. Zinzani, A. Engert, B. Coiffier, D. F. Hoelzer, W. A. Wegener, et al. Multicenter Phase II Trial of Immunotherapy With the Humanized Anti-CD22 Antibody, Epratuzumab, in Combination With Rituximab, in Refractory or Recurrent Non-Hodgkin's Lymphoma J. Clin. Oncol., August 20, 2006; 24(24): 3880 - 3886. [Abstract] [Full Text] [PDF]

				R. Stein, Z. Qu, T. M. Cardillo, S. Chen, A. Rosario, I. D. Horak, H. J. Hansen, and D. M. Goldenberg Antiproliferative activity of a humanized anti-CD74 monoclonal antibody, hLL1, on B-cell malignancies Blood, December 1, 2004; 104(12): 3705 - 3711. [Abstract] [Full Text] [PDF]

				J. D. Burton, S. Ely, P. K. Reddy, R. Stein, D. V. Gold, T. M. Cardillo, and D. M. Goldenberg CD74 Is Expressed by Multiple Myeloma and Is a Promising Target for Therapy Clin. Cancer Res., October 1, 2004; 10(19): 6606 - 6611. [Abstract] [Full Text] [PDF]

				J. P. Leonard, M. Coleman, J. C. Ketas, A. Chadburn, R. Furman, M. W. Schuster, E. J. Feldman, M. Ashe, S. J. Schuster, W. A. Wegener, et al. Epratuzumab, a Humanized Anti-CD22 Antibody, in Aggressive Non-Hodgkin's Lymphoma: Phase I/II Clinical Trial Results Clin. Cancer Res., August 15, 2004; 10(16): 5327 - 5334. [Abstract] [Full Text] [PDF]

				G. L. Griffiths, M. J. Mattes, R. Stein, S. V. Govindan, I. D. Horak, H. J. Hansen, and D. M. Goldenberg Cure of SCID Mice Bearing Human B-Lymphoma Xenografts by an Anti-CD74 Antibody-Anthracycline Drug Conjugate Clin. Cancer Res., December 15, 2003; 9(17): 6567 - 6571. [Abstract] [Full Text] [PDF]

				J. Carnahan, P. Wang, R. Kendall, C. Chen, S. Hu, T. Boone, T. Juan, J. Talvenheimo, S. Montestruque, J. Sun, et al. Epratuzumab, a Humanized Monoclonal Antibody Targeting CD22: Characterization of in Vitro Properties Clin. Cancer Res., September 1, 2003; 9(10): 3982S - 3990. [Abstract] [Full Text] [PDF]

				M. Coleman, D. M. Goldenberg, A. B. Siegel, J. C. Ketas, M. Ashe, J. M. Fiore, and J. P. Leonard Epratuzumab: Targeting B-Cell Malignancies through CD22 Clin. Cancer Res., September 1, 2003; 9(10): 3991S - 3994. [Abstract] [Full Text] [PDF]

				J. P. Leonard, M. Coleman, J. C. Ketas, A. Chadburn, S. Ely, R. R. Furman, W. A. Wegener, H. J. Hansen, H. Ziccardi, M. Eschenberg, et al. Phase I/II Trial of Epratuzumab (Humanized Anti-CD22 Antibody) in Indolent Non-Hodgkin's Lymphoma J. Clin. Oncol., August 15, 2003; 21(16): 3051 - 3059. [Abstract] [Full Text] [PDF]

				D. M. Goldenberg Targeted Therapy of Cancer with Radiolabeled Antibodies J. Nucl. Med., May 1, 2002; 43(5): 693 - 713. [Abstract] [Full Text] [PDF]

				D. L. Newton, H. J. Hansen, S. M. Mikulski, D. M. Goldenberg, and S. M. Rybak Potent and specific antitumor effects of an anti-CD22-targeted cytotoxic ribonuclease: potential for the treatment of non-Hodgkin lymphoma Blood, January 15, 2001; 97(2): 528 - 535. [Abstract] [Full Text] [PDF]

				T. M. Behr, R. D. Blumenthal, S. Memtsoudis, R. M. Sharkey, S. Gratz, W. Becker, and D. M. Goldenberg Cure of Metastatic Human Colonic Cancer in Mice with Radiolabeled Monoclonal Antibody Fragments Clin. Cancer Res., December 1, 2000; 6(12): 4900 - 4907. [Abstract] [Full Text]